Global Regenerative Medicine Market 2018-2022

Global Regenerative Medicine Market 2018-2022

About Regenerative Medicine

Regenerative medicine augments, repairs, replaces or regenerates organs and tissue that have been damaged by disease, injury, or even by the natural aging process.

Technavio’s analysts forecast the global regenerative medicine market to grow at a CAGR of 18.96% during the period 2018-2022.

Covered in this report

The report covers the present scenario and the growth prospects of the global regenerative medicine market for 2018-2022. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:

• Americas
• APAC
• EMEA

Technavio's report, Global Regenerative Medicine Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

• ALLERGAN
• Integra LifeSciences
• Medtronic
• MiMedx Group
• Organogenesis
• Zimmer Biomet

Market driver

• Increasing prevalence of chronic diseases
• For a full, detailed list, view our report

Market challenge

• Uncertain regulatory approval
• For a full, detailed list, view our report

Market trend

• Emerging technological advances
• For a full, detailed list, view our report

Key questions answered in this report

• What will the market size be in 2022 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?

Press Release

Technavio Announces the Publication of its Research Report – Global Regenerative Medicine Market 2018-2022

Technavio recognizes the following companies as the key players in the global regenerative medicine market: ALLERGAN, Integra LifeSciences, Medtronic, MiMedx Group, Organogenesis, and Zimmer Biomet.

Commenting on the report, an analyst from Technavio’s team said: “One trend in the market is emerging technological advances. With the growing demand, vendors in the stem cell therapy market focus on investing in technological advancements such as using regenerated tracheas for transplant and 3D bioprinting to survive in this competitive market.”

According to the report, one driver in the market is increasing prevalence of chronic diseases. According to the Centers for Disease Control and Prevention (CDC), over 117 million individuals in the US had one of more chronic health conditions in 2012. Moreover, there is also an increase in the prevalence of acute wounds such as surgical and traumatic wounds across the globe and it has been observed that the global prevalence of surgical wounds was about 135,000 in 2016.

Further, the report states that one challenge in the market is uncertain regulatory approval. Cell therapy, gene therapy, and tissue engineering have been under development for several decades. However, their successful clinical application is still considered to be a recent phenomenon in both developed and developing countries.